Grassi Investment Management trimmed its holdings in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 0.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 124,577 shares of the healthcare product maker’s stock after selling 704 shares during the quarter. Abbott Laboratories comprises about 1.2% of Grassi Investment Management’s investment portfolio, making the stock its 19th largest holding. Grassi Investment Management’s holdings in Abbott Laboratories were worth $14,203,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also bought and sold shares of ABT. Unique Wealth Strategies LLC acquired a new stake in shares of Abbott Laboratories during the 2nd quarter worth approximately $28,000. Redmont Wealth Advisors LLC bought a new position in Abbott Laboratories in the first quarter valued at about $30,000. Future Financial Wealth Managment LLC acquired a new stake in shares of Abbott Laboratories during the third quarter valued at about $31,000. Itau Unibanco Holding S.A. acquired a new stake in Abbott Laboratories during the 2nd quarter worth approximately $32,000. Finally, Ridgewood Investments LLC bought a new position in shares of Abbott Laboratories during the second quarter valued at $37,000. Institutional investors and hedge funds own 75.18% of the company’s stock.
Insider Transactions at Abbott Laboratories
In other news, CEO Robert B. Ford sold 141,679 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the completion of the transaction, the chief executive officer now owns 220,059 shares in the company, valued at approximately $25,617,068.19. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.10% of the company’s stock.
Analyst Ratings Changes
View Our Latest Stock Analysis on ABT
Abbott Laboratories Trading Up 0.7 %
ABT stock opened at $116.99 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.68 and a debt-to-equity ratio of 0.33. The company’s 50-day simple moving average is $114.46 and its 200-day simple moving average is $108.62. The firm has a market cap of $203.52 billion, a P/E ratio of 36.45, a PEG ratio of 2.74 and a beta of 0.72. Abbott Laboratories has a 52-week low of $91.64 and a 52-week high of $121.64.
Abbott Laboratories (NYSE:ABT – Get Free Report) last announced its quarterly earnings data on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The firm had revenue of $10.64 billion for the quarter, compared to analyst estimates of $10.55 billion. During the same quarter in the prior year, the company posted $1.14 earnings per share. Abbott Laboratories’s quarterly revenue was up 4.9% on a year-over-year basis. As a group, equities analysts forecast that Abbott Laboratories will post 4.66 EPS for the current fiscal year.
Abbott Laboratories Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date is Tuesday, October 15th. Abbott Laboratories’s dividend payout ratio is currently 68.54%.
Abbott Laboratories Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Read More
- Five stocks we like better than Abbott Laboratories
- 3 Best Fintech Stocks for a Portfolio Boost
- A $1.75 Billion Gamble: Can Lucid Ignite Growth?
- What Are Dividend Contenders? Investing in Dividend Contenders
- The Rally in Lockheed Martin and RTX Can Continue: Here’s Why
- How to Calculate Options Profits
- 3 Undervalued Technology Stocks With Big Rebound Potential
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.